Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser, Hui Hao-Shen, Ina Nissen, Sabine Girsberger, Thomas Lehmann, Jakob Passweg, Martin Stern, Christian Beisel, Robert Kralovics, Radek C. Skoda

Blood (2014) 123 (14): 2220–2228.

https://doi.org/10.1182/blood-2013-11-537167

Published: 2014

Includes: Supplemental data

Journal Articles

Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia

Jean Grisouard, Mario Ojeda-Uribe, Renate Looser, Hui Hao-Shen, Pontus Lundberg, Adrian Duek, Eric Jeandidier, Axel Karow, Radek C. Skoda

Blood (2013) 122 (22): 3694–3696.

https://doi.org/10.1182/blood-2013-07-516385

Published: 2013

Journal Articles

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Rouven Müller, MD, Alexandre Theocharides, MD, Renate Looser, Radek C. Skoda, M.D., Richard A. Flavell, PhD, Markus G. Manz, MD

Blood (2013) 122 (21): 2844.

https://doi.org/10.1182/blood.V122.21.2844.2844

Published: 2013

Journal Articles

Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2

Franz X. Schaub, Thomas Lehmann, Renate Looser, Hui Hao-Shen, Andre Tichelli, Radek C. Skoda

Blood (2011) 117 (6): 2075–2076.

https://doi.org/10.1182/blood-2010-11-316471

Published: 2011

Journal Articles

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

Franz X. Schaub, Renate Looser, Sai Li, Hui Hao-Shen, Thomas Lehmann, Andre Tichelli, Radek C. Skoda

Blood (2010) 115 (10): 2003–2007.

https://doi.org/10.1182/blood-2009-09-245381

Published: 2010

Includes: Supplemental data

Journal Articles

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Silke Kapp-Schwoerer, Renate Looser, Franz Schaub, Michael Hummel, Manfred Olschewski, Jens Hasskarl, Michael Lübbert, MD, PhD, Ulrich Germing, Radek C. Skoda, MD, Annette H Schmitt-Graeff

Blood (2009) 114 (22): 3101.

https://doi.org/10.1182/blood.V114.22.3101.3101

Published: 2009

Journal Articles

Clonal analysis of deletions on chromosome 20q and JAK2 -V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2 -V617F

Franz X. Schaub, Roland Jäger, Renate Looser, Hui Hao-Shen, Sylvie Hermouet, François Girodon, Andre Tichelli, Heinz Gisslinger, Robert Kralovics, Radek C. Skoda

Blood (2009) 113 (9): 2022–2027.

https://doi.org/10.1182/blood-2008-07-167056

Published: 2009

Journal Articles

Ratio of mutant JAK2 -V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Ralph Tiedt, Hui Hao-Shen, Marta A. Sobas, Renate Looser, Stephan Dirnhofer, Jürg Schwaller, Radek C. Skoda

Blood (2008) 111 (8): 3931–3940.

https://doi.org/10.1182/blood-2007-08-107748

Published: 2008

Includes: Supplemental data

Journal Articles

The JAK2-V617F Mutation Load Remains Stable over Several Years in Most Patients with Myeloproliferative Disorders Analyzed in a Retrospective Single Center Study.

Alexandre Theocharides, MD, Renate Looser, Hao-Shen Hui, Andreas S. Buser, MD, Alois Gratwohl, MD, Andre Tichelli, MD, Radek C. Skoda, MD

Blood (2007) 110 (11): 2526.

https://doi.org/10.1182/blood.V110.11.2526.2526

Published: 2007

Journal Articles

Ratio of Mutant JAK2-V617F to Wild Type Jak2 Determines the MPD Phenotypes in Transgenic Mice.

Ralph Tiedt, PhD, Hui Hao-Shen, MSc, Marta A. Sobas, MD, Renate Looser, Stephan Dirnhofer, MD, Jürg Schwaller, MD, Radek C. Skoda, MD

Blood (2007) 110 (11): 674.

https://doi.org/10.1182/blood.V110.11.674.674

Published: 2007

NARROW

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Clonal analysis of deletions on chromosome 20q and JAK2 -V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2 -V617F

Ratio of mutant JAK2 -V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

The JAK2-V617F Mutation Load Remains Stable over Several Years in Most Patients with Myeloproliferative Disorders Analyzed in a Retrospective Single Center Study.

Ratio of Mutant JAK2-V617F to Wild Type Jak2 Determines the MPD Phenotypes in Transgenic Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only